Pfizer - STAT

Pharmalot By Ed Silverman

Doctors Without Borders chastises Pfizer for refusing to lower vaccine price

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: To avoid scandal, Novartis CEO advises companies not to hire rulebreakers

Pharmalot By Ed Silverman

Pfizer won’t split into two companies, so what’s next?

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Pfizer decides not to split into two companies

Pharmalot By Ed Silverman

FDA panel votes to remove serious warning from Pfizer’s smoking cessation pill

Pharmalot By Ed Silverman

FDA reviewers question Pfizer study about safety of its Chantix smoking cessation pill

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Pfizer CEO says Clinton drug pricing plan is ‘very negative’

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Are concerns about spending on orphan drugs overblown?

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Docs disciplined for misconduct still paid by pharma to be speakers, advisers

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: India wants you to know its drugs are safe and effective

Business By Associated Press

Pfizer buying Medivation in deal valued at about $14 billion

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Pfizer pays $14 billion for Medivation and its prostate cancer drug

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: North Korea’s Neo-Viagra has the same ingredient as the real thing

Pharmalot By Ed Silverman

Pfizer closes plant in India after several regulators find problems

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Bristol-Myers cancer drug misses main goal in late-stage study

Pharmalot By Ed Silverman

Most Read

Pfizer sues Texas agency over releasing Medicaid data to lawmakers

After a long battle, Pfizer drops the price of its Prevnar vaccine to humanitarian groups

Pharmalot, Pharmalittle: Pfizer may sell or spin off its consumer business

Up and down the ladder: The latest comings and goings

Pfizer stops developing a cholesterol drug. So who is the big winner?

Pharmalot, Pharmalittle: Is the 21st Century Cures bill in doubt over drug prices?

Pfizer fined again for violating environmental law at Puerto Rico plant

Interfaith investor coalition pushes shareholder resolutions on drug prices

All Coverage

Doctors Without Borders chastises Pfizer for refusing to lower vaccine price

Pharmalot, Pharmalittle: To avoid scandal, Novartis CEO advises companies not to hire rulebreakers

Pfizer won’t split into two companies, so what’s next?

Pharmalot, Pharmalittle: Pfizer decides not to split into two companies

FDA panel votes to remove serious warning from Pfizer’s smoking cessation pill

FDA reviewers question Pfizer study about safety of its Chantix smoking cessation pill

Up and down the ladder: The latest comings and goings

Pharmalot, Pharmalittle: Pfizer CEO says Clinton drug pricing plan is ‘very negative’

Pharmalot, Pharmalittle: Are concerns about spending on orphan drugs overblown?

Pharmalot, Pharmalittle: Docs disciplined for misconduct still paid by pharma to be speakers, advisers

Pharmalot, Pharmalittle: India wants you to know its drugs are safe and effective

Pfizer buying Medivation in deal valued at about $14 billion

Pharmalot, Pharmalittle: Pfizer pays $14 billion for Medivation and its prostate cancer drug

Pharmalot, Pharmalittle: North Korea’s Neo-Viagra has the same ingredient as the real thing

Pfizer closes plant in India after several regulators find problems

Pharmalot, Pharmalittle: Bristol-Myers cancer drug misses main goal in late-stage study

Pharmalot, Pharmalittle: Brexit, schmexit. Glaxo invests $360 million in the UK